Formulations and methods for treating hypercoagulable states

Details Formulations and methods for treating hypercoagulable states Formulations and methods for treating hypercoagulable states

2006-08-08

2006-08-08

Witz, Jean C. (Department: 1651)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600

Reexamination Certificate

active

07087578

ABSTRACT:
A method of treating a human patient with a hypercoagulable state or protein C deficiency, which comprises administering activated Protein C and protein C Zymogen.

REFERENCES:
patent: 4775624 (1988-10-01), Bang et al.
patent: 4849403 (1989-07-01), Stocker et al.
patent: 4877608 (1989-10-01), Lee et al.
patent: 4981952 (1991-01-01), Yan
patent: 4992373 (1991-02-01), Bang et al.
patent: 5009889 (1991-04-01), Taylor et al.
patent: 5084273 (1992-01-01), Hirahara
patent: 5084274 (1992-01-01), Griffin et al.
patent: 5093117 (1992-03-01), Lawrence et al.
patent: 5112949 (1992-05-01), Vukovich
patent: 5175087 (1992-12-01), Ranby et al.
patent: 5358932 (1994-10-01), Foster et al.
patent: 5395923 (1995-03-01), Bui-Khac et al.
patent: 5413732 (1995-05-01), Buhl et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5453523 (1995-09-01), Griffith et al.
patent: 5478558 (1995-12-01), Eibl et al.
patent: 5516650 (1996-05-01), Foster et al.
patent: 5831025 (1998-11-01), Ogata et al.
patent: 5962299 (1999-10-01), Miyata et al.
patent: 6008199 (1999-12-01), Grinnell
patent: 6156734 (2000-12-01), Grinnell
patent: 6159468 (2000-12-01), Carlson et al.
patent: 6162629 (2000-12-01), Baker
patent: 6268344 (2001-07-01), Grinnell
patent: 6395270 (2002-05-01), Carlson et al.
patent: 6436397 (2002-08-01), Baker et al.
patent: 6489296 (2002-12-01), Grinnell et al.
patent: 3823519 (1990-01-01), None
patent: 314 095 (1988-10-01), None
patent: 315 968 (1988-11-01), None
patent: 318 201 (1988-11-01), None
patent: 326 014 (1989-01-01), None
patent: 357 296 (1989-08-01), None
patent: 445 939 (1991-02-01), None
patent: 726 076 (1994-10-01), None
patent: 662 513 (1995-01-01), None
patent: 0 875 252 (1998-11-01), None
patent: 01226900 (1989-09-01), None
patent: 7097335 (1995-04-01), None
patent: 07165605 (1995-06-01), None
patent: 8301786 (1996-11-01), None
patent: 8325161 (1996-12-01), None
patent: WO 91/12320 (1991-02-01), None
patent: WO 95/11966 (1995-04-01), None
patent: WO 97/20043 (1997-06-01), None
patent: WO 98/48818 (1998-11-01), None
U.S. Appl. No. 09/545,175, filed Apr. 6, 2000.
Natanson, et al. “Anti-Inflammatory Therapies to Treat Sepsis and Septic Shock: A Reassessment”, Crit. Care Med. 25:1095-1100, 1997.
Barbour, et al., “Controversies in Thromboembolic Disease During Pregnancy: A Critical Review”, Obstet. Gynecol. 86(4):621-633, 1995.
Bazarbachi, et al., “Changes in Protein C, Factor VII and Endothelial markers After Autologous Bone Marrow Transplantation: Possible Implications in the Pathogenesis of Veno-Occlusive Disease,” Nouv Rev Fr Hematol 35:135-140,1993.
Blamey, et al., “Protein C Antigen Levels in Major Abdominal Surgery:Relationships to Deep Vein Thrombosis, Malignancy and Treatment with Stanozolol”, Thromb. Haemost. 54:622-625, 1985.
Butler, et al., “Yersinia pestisInfection in Vietman. I. Clinical and Hematologic Aspects”, The Journal of Infectious Disease 129:S78-S84; 1974.
Carpenter, et al., Purpura Fulminans in Pneumococcal Sepsis: Case Report and Review', Scand J Infect Dis 29:479-483, 1997.
Collins, et al., “Factor VIIa and Other Haemostatic Variables Following Bone Marrow Transplantation”, Throm. And Haemo. 72:28-32, 1994.
Collins, et al., “Pitfalls in Peripheral Vascular Surgery: Disseminated Intravascular Coagulation”, Am. J. Surgery 124:375-380, 1977.
Conrad, et al., “Thrombosis and Pregnancy in Congenital Deficiencies in AT III, Protein C or Protein S: Study of 78 Women”, Throm. Haemost. 63 (2) :319-320, 1990.
Curreri, et al., “Coagulation Dynamics Following Thermal Injury”, Ann.Surc. 181:161-163, 1974.
Dahlback, et al., “Inherited Thrombophilia: Resistance to Activated Protein C as a Pathogenic Factor of Venous Thromboembolism”, Blood 85(3):607-614, 1995.
Database Medline, AN91073823, Pyzh M.V., et al., “Effects of low doses of activated protein C in experimental arterial thrombosis in rats”, XP002069505 abstract.
De Stefano, et al., “Thrombotic Risk During Pregnancy and Puerperium in Woman with APC-Resistance—Effective Subcutaneous Heparin Prophylaxis lin a Pregnancy Patient”, ThrombHaemost 74:793-794, 1995.
Esmon, “The Protein C Anticoagulant Pathway”, Arteriosclerosis & Thromb. 12:135-145, 1992.
Esmon, C.T., “The Regulation of Natural Anticoagulant Pathways” Science, vol. 235, pp. 1348-1352 (Mar. 1987).
Faioni, et al., “Naturally Occurring Anticoagulants and Bone Marrow Transplantation: Plasma Protein C Predicts the Development of Venocclusive Disease of the Liver,” Blood 81:3458-3462, 1993.
Fourrier, et al., “Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation”, Chest 101:816-823, 1992.
Franz, et al., “Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents”, Journal of the American Medical Assoc. 278(5):399-411, 1997.
Gerson, et al., “Severe Acquired Protein C Deficiency in Purpura Fulminans Associated with Disseminated Intravascular Coagulation: Treatment with Protein C Concentrate”, Pediatrics 91(2):418-422, 1993.
Gibaldi, Anatomy of an Antibody, and Related Misadventures in Developing an Effective Treatment for Septic Shock,, Pharmacotherapy 13(4):302-308, 1993.
Gordon, et al., “Thrombotic Complications of BMT: Association with Protein C Deficiency”, Bone Marrow Transplan. 11:61-65, 1993.
Graybill, et al., “Complement and Coagulation in Rocky Mountain Spotted Fever”, Southern Medical Journal 66(4):410-413, 1973.
Grinnell, et al., Trans-Activated Expression of Fully Gamma-Carboxylated Recombinant Human Protein C, an Antithrombotic Factor, Bio/Technolocay 5:1189-1192, 1987.
Haire, et al., “Multiple Organ Dysfunction Syndrome in Bone Marrow Transplantation,” JAMA 274:1289-1295, 1995.
Harper, et al., “Changes in the Natural Anticoagulants Following Bone Marrow Transplantation”, Bone Marrow Trans. 5:39-42, 1990.
Harper, et al., “Protein C Deficiency and Portal Thrombosis in Liver Transplantation in Children”, Lancet 924-927, 1988.
Hill, et al., “Leptospiral Pneumonia”, Seminars in Respiratory Infections 12(1):44-49, 1997.
Howey, et al., Preparation for Trials of Recombinant Activated Protein C in Sepsis: A pharmacoknietic and Dynamic Study in Healthy Men and Women', Chest 112(3) : 89S, 1997.
Koul, et al., Haemostatic Abnormalities in Multidrug-Resistant Enteric Fever', Acta Haematol 93:13-19, 1995.
Leclerc, J.R., “Low-Molecular Weight Heparin Prophylaxis in Surgical Patients”, Clin. Appl. Thrombosis/Hemostasis 3(3):153-156, 1997.
Lercari,et al., “Apheresis for SevereMalaria Complicated by Cerebral Malaria, Acute Respiratory Distress Syndrome, Acute Renal Failure, and Disseminated Intravascular Coagulation”, Journal of Clinical Apheresis 7:93-96, 1992.
Levi, et al., “Pathogenesis of Disseminated Intravascular Coagulation in Sepsis”, JAMA 270:975-979, 1993.
Levin, “Syndromes with Renal Failure and Shock”, Pediatric Nevhroloav 8:223-229, 1994.
Lo, et al., “Protein C and Protein S Levels in Some Burn Patients”, Burns 20:186, 1994.
Loubser, et al., “Severe Illness caused byRickettsia conorii”, Annals of Tropical Paediatrics 13:277-280, 1993.
Maraganore, “Hirudin and Hirulog” :Advances in Antithrombotic Therapy, Perspective in Drua Discovery and Design 1:461-478, 1994.
Mayer, et al., “Coagulopathies Associated with Major Spinal Surgery”, Clin. Orthop. 245:83-88, 1989.
McManus, et al., “Disseminated Intravascular Coagulation in Burned Patients”, J. of Trauma 13(5):416-422, 1973.
Menges, et al., “The Role of the Protein C-Thrombomodulin System and Fibrinolysis During Cardiovascular Surgery: Influence of Actue Preoperative Plasmapheresis”, J. Cariothor Vasc An. 10:482-489, 1996.
Mesters, et al., “Factor VIIa and Antithrombin III Act

Affiliated with

Also associated with

Rating

Formulations and methods for treating hypercoagulable states does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations and methods for treating hypercoagulable states, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations and methods for treating hypercoagulable states will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3657429